CMMB Chemomab Therapeutics Ltd - ADR

$CMMB Why do people care what Erik Otto is doing with CMMB?? The thesis here is pretty simple. $30M PIPE is at $6.X (but $15M warrants at $3). + 5$ CVR for getting to ph3 for PSC + funded through ph2 readout for RA No matter if another buyer is stepping in before the merger (seems unlikely to me) CMMB still seems very cheap (but need the S4 first to make sure)

$CMMB NEW CONFIRMED FACTS 50,000 PrismRA tests — updated from 45,000 mentioned earlier. Growing faster than previously disclosed. 30+ RA clinical sites from the PREDICT study — Scipher has an existing clinical network ready to enroll Phase 2 patients immediately. IND submission H2 2026 — they are submitting the RA IND this year, before merger close. This is significant — it demonstrates the RA program is real and advancing independently. THE PSC LANGUAGE — FOURTH CONSECUTIVE STATEMENT Adi Mor said: "it is important to emphasize that PSC, a potential lethal disease with no FDA-approved drugs, remains an important opportunity for nebokitug, potentially via partnering."  The Wainwright presentation confirms the deal is proceeding, the RA thesis is credible, and management continues to publicly signal PSC partnership availability for the fourth consecutive time

$CMMB One more chunk of 25k tomorrow AM and then I'm done for a while. Will be sitting on 300k total. You have been warned....a THIRD TIME!!!!

$CMMB Gwen Melincoff was brought onto the board 37 days before the Scipher merger announcement not to help execute the reverse merger — but to position Chemomab for what comes after it. Her CLP credential, her Shire/New River relationships, and her 25-year pharma BD network are irrelevant to a reverse merger with an AI diagnostics company. They are precisely relevant to negotiating a PSC licensing deal or facilitating a full platform acquisition post-merger. The 37-day timing is not suspicious. It is strategic. Management appointed the right person for the right job before making the public announcement that would start the clock on that job. She is there for the PSC deal. The Scipher merger is just the setup.

$CMMB After my $CYCN merger is complete next week I'll be buying 25-50k more $CMMB, likely Tuesday or Wednesday at the latest. You have been warned.....AGAIN lol Currently holding 250k shares at ~$2.40 / share avg.

$CMMB 25k more incoming at market open. Fair warning for the 3rd time to all my Chemomabbians!

$CMMB last few days short volume has exceeded 125k shares per day.. Currently only 7K available with 140% borrow rate. They are defending the $3 level so with some decent volume and a push through $3 we can see a nice push to $3.50

$CMMB Grok estimates the PrismRA to be $100M over 5 years. So about $20M per year. Then there is additional revenue from SPECTRA and Immunology, which could be from $5-10M. So an estimate should be roughly $25-30M per year in revenue. Plus $30M cash. Plus PSC partnership catalyst on top of that. Thats the story with Scipher going forward. The PR today contained a lot of information that goes on a S-4, so I assume they could make it public any day now.

$CMMB Zdxss1: Although you block everyone and talk to the wall 😅: Here is a gift from me, where Otto, previous 7% owner, admitting it today. So it is indeed real 😉

$CMMB The reason is because there is a loser of a retail investor that sell 5k shares several times per day. This weak cuck boy have been doing it for atleast 2 weeks straight 💩

$CMMB 10k shares abailable to short literally with borrow rate of 164! Bears going to be slaughtered soon

$CMMB isn’t this merger pretty much a done deal?  Can another company really come in and put another offer in on the table?

$CMMB short interest down to 102K (35k avail at 112% borrow rate) Anyone listen to the HC Wainwright presentation?? Thoughts?

$CMMB You say that Gwen Melincoff is there to help facilitate a full platform acquisition after the merger. This means Scipher will take 68% of the acquisition value, even though it didn’t pay a single dollar. Even a blind man can see this is clearly theft. Why doesn’t Gwen Melincoff help secure a better deal or a full acquisition before the merger — is it forbidden? The matter hides things we don’t know. A drug like CM‑101, with exceptional regulatory, medical, and commercial results, does not deserve a merger of this kind

$CMMB people’s fear and uncertainty is at MM’s advantage and they are grabbing those shares 😉

$CMMB I believe this game is being played by the big players, not retail investors; it seems more like an accumulation process by large institutions than anything else. But your analysis is excellent 😂😂

$CMMB noticed that many of bulls who have blocked me before, keep unblocking back and forth to see what i post. 😅😅😅

$CMMB Management continues, for the fourth consecutive time, to publicly signal that the PSC program is available for partnership. This means the possibility of a better offer is still on the table, which is a positive sign

$CMMB it always acts the same: Pump 2-3 months, trap more poor people, Then drops hard in 2 days 🤣🤣🤣🤣 Wait for it, will come soon